Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 May 23;29(13):102379.
doi: 10.1016/j.jaccas.2024.102379. eCollection 2024 Jul 3.

Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

Omid Kiamanesh  1   2 , Steven C Greenway  3 , Franciscus Dicke  3 , Brennan Ballantyne  1   2 , Sasha Mitrovic  2 , Kaitlin McGrath  1 , James A White  1   4 , William D T Kent  5 , Gregor Andelfinger  6
Affiliations
Case Reports

Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

Omid Kiamanesh et al. JACC Case Rep. .

Abstract

RASopathies cause nonsarcomeric hypertrophic cardiomyopathy via dysregulated signaling through RAS and upregulated mitogen-activated protein kinase activity. We provide the first report of the successful treatment of an adult with RAF1-associated hypertrophic cardiomyopathy using trametinib, a MEK inhibitor.

Keywords: Noonan syndrome; RASopathies; cardiovascular genetics; hypertrophic cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Electrocardiogram Showing Left Ventricular Hypertrophy Electrocardiogram shows normal sinus rhythm, right atrial abnormality, left ventricular hypertrophy with repolarization abnormality, and nonspecific T-wave abnormality.
Figure 2
Figure 2
Echocardiogram Showing an LVOT Gradient of 213 mm Hg Transthoracic echocardiogram (apical 3-chamber) spectral Doppler assessment showing a peak left ventricular outflow tract gradient of 213 mm Hg while on therapy with beta-blockers and disopyramide.
Figure 3
Figure 3
Cardiac Magnetic Resonance Imaging Showing Severe Ventricular Hypertrophy Cardiac magnetic resonance imaging with late gadolinium enhancement showing septal dominant hypertrophy with a maximal wall thickness of 36 mm, leading to systolic anterior motion of the mitral leaflets, a left ventricular apical aneurysm and a small (approximately 9%) burden of late gadolinium enhancement.
Figure 4
Figure 4
Echocardiogram Post-Trametinib Showing a Marked Improvement in the LVOT Gradient Transthoracic echocardiogram (apical 3-chamber) spectral Doppler assessment showing a peak left ventricular outflow tract gradient of 41 mm Hg following treatment with trametinib.
Figure 5
Figure 5
Cardiac MRI After Treatment With Trametinib Cardiac magnetic resonance imaging following treatment with trametinib showed no objective differences with respect to maximal wall thickness, global left ventricular mass, left ventricular aneurysm, or myocardial fibrosis; however, a visible reduction in severity of systolic anterior motion was present.
See this image and copyright information in PMC

References

    1. Arbelo E., Protonotarios A., Gimeno J.R., et al. ESC Scientific Document Group 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626. doi: 10.1093/eurheartj/ehad194. - DOI - PubMed
    1. Calcagni G., Adorisio R., Martinelli S., et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies. Heart Fail Clin. 2018;14(2):225–235. doi: 10.1016/j.hfc.2017.12.00. - DOI - PubMed
    1. Mussa A., Carli D., Giorgio E., et al. MEK inhibition in a newborn with RAF1-associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease. Genes (Basel) 2021;13(1):6. doi: 10.3390/genes13010006. - DOI - PMC - PubMed

Publication types